Business
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020 Interim Analysis Results for Phase 3 RELIEF
About this update from Tonix Pharmaceuticals Holding Corp.
[{"type":"text","content":"Preclinical data for TNX-1800, a Vaccine Candidate to Protect Against COVID-19, Expected in Fourth Quarter 2020\n Interim Analysis Results for Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia Expected in September 2020 Topline Data for RELIEF Trial Expected in Fourth Quarter 2020 NEW YORK, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2020, and provided an overview of recent operational highlights. “The second quarter was highlighted by exciting progress for our lead immunology and central nervous system product candidates,” said Seth Lederman, M.D., President and Chief Executive Officer. “We expect to have the first data from animal studies of our lead COVID-19 vaccine candidate, TNX-1800, in the fourth quarter of this year. TNX-1800 is a live attenuated vaccine based on our proprietary horsepox vector system that carries a gene encoding the Spike protein from SARS-CoV-2, the virus that causes COVID-19. We have also continued to progress the Phase 3 RELIEF study of TNX-102 SL for fibromyalgia, having reached 50% enrollment in April and then completing enrollment in July, ahead of schedule. We look forward to interim data in September and topline results from the RELIEF study by the end of this year.” Recent Highlights Research and Development COVID-19 vaccine candidate TNX-1800 (live attenuated vaccine based on horsepox virus vector) designed as a single-shot vaccine to elicit T cell immunity In June, Tonix announced an agreement with FUJIFILM Diosynth Biotechnologies to provide contract manufacturing and development services to support the manufacturing of TNX-1800 for clinical trial supply.Tonix expects small animal and non-human primate data from safety studies of TNX-1800 in COVID-19 models to measure safety and the immune response to the SARS-COV-2 Spike protein in the fourth quarter of 2020. In addition, we also expect data from non-human primate studies to measure efficacy in challenge studies using SARS-COV-2 in the fourth quarter. COVID-19 research collaboration with Southern Research In June, Tonix announced a new collaboration with Southern Research to study T cell immune responses to SARS-CoV-2 in volunteers who have re...